Altos Capital Partners
Altos Capital Partners LLC is a principal investment firm located in Los Altos, California, that focuses on investing in seed to growth stage companies. The firm engages with a diverse array of sectors, including technology, real estate, and energy, seeking opportunities that demonstrate strong potential for development and expansion. By targeting various industries, Altos Capital Partners aims to foster innovation and support the growth of emerging businesses.
Top Regions
2 past transactions
Epic Sciences
Series E in 2018
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.
Epic Sciences
Series D in 2017
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.